A Study of Eltrekibart (LY3041658) in Healthy Participants

← catalyst calendar

NCT07545590 · readout ≤ 12 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Basic science

Enrollment

60estimated

Sites

Country

Singapore

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-21

actual

When the study began enrolling

Primary completion

Aug 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2026

estimated

The whole study's end, after follow-up

First posted

2026-04-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy

Interventions

Drug: LY3041658 — also filed as Eltrekibart
Drug: LY3041658 — also filed as Eltrekibart

Primary outcomes

what the primary-completion date above is the date OF

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658

measured Predose on Day 1 up to Day 85

PK: Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3041658

measured Predose on Day 1 up to Day 85

PK: Area Under the Concentration Versus Time Curve From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration AUC(0-tlast) of LY3041658

measured Predose on Day 1 up to Day 85

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed